Close

Maxim Reaffirms Galena Biopharma (GALE) at 'Buy' NeuVax Phase 3, PRESENT Reaches Halfway Point

March 29, 2016 2:13 PM EDT Send to a Friend
Maxim reaffirms its Buy rating and $4 price target on Galena Biopharma, Inc. (Nasdaq: GALE) after the company announced that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login